What one share of MapLight Therapeutics holds
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.
MapLight Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$7.47 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$5.69 |
| Cash and investments | $1.58 |
| Book value | $7.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$105.38 | $1.05 | −$108.11 | — | −$254.35 |
| 2025 | — | −$18.56 | $0.05 | −$15.97 | — | $10.41 |
Common questions about MapLight Therapeutics
How much does one share of MapLight Therapeutics earn?
Over the last 12 months, MapLight Therapeutics lost $7.47 for each share.
Does MapLight Therapeutics pay a dividend?
MapLight Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is MapLight Therapeutics’s book value per share?
MapLight Therapeutics’s book value is $7.67 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of MapLight Therapeutics have?
Each share of MapLight Therapeutics has $1.58 of cash and investments, as of June 30, 2026.
What is MapLight Therapeutics’s free cash flow per share?
−$5.69 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.